Cargando…
DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
The rising prevalence of diabetes is threatening global health. It is known not only for the occurrence of severe complications but also for the SARS-Cov-2 pandemic, which shows that it exacerbates susceptibility to infections. Current therapies focus on artificially maintaining insulin homeostasis,...
Autores principales: | Barzowska, Agata, Pucelik, Barbara, Pustelny, Katarzyna, Matsuda, Alex, Martyniak, Alicja, Stępniewski, Jacek, Maksymiuk, Anna, Dawidowski, Maciej, Rothweiler, Ulli, Dulak, Józef, Dubin, Grzegorz, Czarna, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467532/ https://www.ncbi.nlm.nih.gov/pubmed/34571911 http://dx.doi.org/10.3390/cells10092263 |
Ejemplares similares
-
Binding mechanism and biological effects of flavone DYRK1A inhibitors for the design of new antidiabetics
por: Pustelny, Katarzyna, et al.
Publicado: (2023) -
DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets
por: Pucelik, Barbara, et al.
Publicado: (2023) -
Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration
por: Pucelik, Barbara, et al.
Publicado: (2021) -
Silmitasertib
(CX-4945), a Clinically Used CK2-Kinase
Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases:
A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023) -
Compromised diabetic heart function is not affected by miR-378a upregulation upon hyperglycemia
por: Florczyk-Soluch, Urszula, et al.
Publicado: (2023)